Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1 integrin inhibitor, in primary sclerosing cholangitis.

Saved in:
Bibliographic Details
Title: Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6vβ1 integrin inhibitor, in primary sclerosing cholangitis.
Authors: Hirschfield GM; The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, ON, Canada. Electronic address: Gideon.Hirschfield@uhn.ca., Kowdley KV; Liver Institute Northwest, Seattle, WA, USA; Elson S. Floyd College of Medicine, Washington State University, Seattle, WA, USA., Trivedi PJ; NIHR Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, UK; Liver Unit, University Hospitals Birmingham, Birmingham, UK., Eksteen B; Aspen Woods Clinic, Calgary, AB, Canada., Hameed B; University of California San Francisco School of Medicine, San Francisco, CA, USA., Vincent C; Liver Unit, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada., Chen T; Department of Medicine, McGill University Health Centre, Montreal, QC, Canada., Goel A; Stanford University, Palo Alto, CA, USA., Reddy KG; Department of Medicine, University of Chicago, Chicago, IL, USA., Orman E; Indiana University School of Medicine, Indianapolis, IN, USA., Joshi D; Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK., Lefebvre ÉA; Pliant Therapeutics, Inc, South San Francisco, CA, USA., Schaub JR; Pliant Therapeutics, Inc, South San Francisco, CA, USA., An MC; Former employees of Pliant Therapeutics, Inc, South San Francisco, CA, USA., Clark A; Former employees of Pliant Therapeutics, Inc, South San Francisco, CA, USA., Barnes CN; Pliant Therapeutics, Inc, South San Francisco, CA, USA., Pencek R; Former employees of Pliant Therapeutics, Inc, South San Francisco, CA, USA., Thorburn D; Sheila Sherlock Liver Centre and UCL Institute for Liver and Digestive Health, London, UK., Montano-Loza AJ; Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, AB, Canada., Schramm C; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bowlus CL; University of California, Davis, Sacramento, CA, USA., Trauner M; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria., Levy C; Schiff Center for Liver Diseases, University of Miami, Miami, FL, USA.
Source: Journal of hepatology [J Hepatol] 2026 Jan; Vol. 84 (1), pp. 86-98. Date of Electronic Publication: 2025 Sep 26.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1600-0641
DOI:10.1016/j.jhep.2025.09.016